DTM 2025 Resource Hub –
Welcome to our resource hub for the Diabetes Technology Meeting (DTM) 2025! This is a one-stop-shop for all your DTM 2025 needs. We will be updating the resource hub daily, so check back in for the latest on this fantastic meeting.
Important Conference Information. We are so excited to see the return of DTM 2024 in-person this year, taking place at the San Francisco Airport Marriott Waterfront in Burlingame, CA October 28-30. Attendees will have access to all workshops taking place October 28th, and will receive a one-year subscription to Journal of Diabetes Science and Technology.
Conference Recording Availability. DTM 2025 will not be available virtually, nor will sessions be available on-demand.
Table of Contents []
Useful Conference Links
Day-of Conference Reports
Top Highlights
- CGM or GLP-1 RAs: Lively debate discusses which option is more useful for diabetes treatment
- Not all AID algorithms are alike: A comparative look at modern systems
- Murphy’s Law in AID systems: Dr. Edelman on safe and smart AID use
- Redefining AID eligibility: Dr. Halis Akturk advocates for early and inclusive use of the technology
- Dr. Rich Bergenstal on the evolving role of the ambulatory glucose profile and how to improve clinical relevance
- CGM for hospitals: Current limitations and future opportunities
- Diabetes data interoperability: iCoDE-2’s model for insulin data management and European perspectives on device regulation
- Presentation of CGM data: Actionable insights and new dimensions
- Newly published phase 3 trial demonstrates the role of AI in diabetes prevention
- Integrating autonomous AI into diabetes care to improve diabetic retinopathy screening in youth
- Fragmentation of care: Growing number of CGM and insulin delivery options complicates provider management
- Glycated albumin as a once-weekly home testing method for non-insulin T2D management
- Dr. Rich Bergenstal emphasized the use of CGM metrics and profiles to advance personalization of diabetes care
- AID without meal announcements: The efficacy and synergistic effects in people with T1D
- Making diabetes technology work for everyone: Impassioned panelists tackle access, education, and innovation
- Advancing diabetes care through technology: A tech-specific review of the ADA 2025 Standards of Care with Dr. Rita Kalyani
- Artificial Pancreas Award: Prof. Mohammed Al-Sofiani recognized for his work on AID systems for Ramadan fasting
- Diabetes Technology Leadership Award: Mr. Shahid Shah awarded honor for his work advancing AI infrastructure
- Escaping the “ceiling of improvement”: Neural networks for improved AID control
- Leaders across diabetes technology highlight AI’s role in patient-centered diabetes care
- Abbott spotlights CGM impact in T2D and looks ahead to real-time ketone monitoring
- TITR gains attention across pediatric and adult diabetes care
- Advancing inpatient glycemic management through CGM and automated insulin dosing algorithms
- Greater detail in fewer digits: Dr. Viral Shah on Glycemia Risk Index
- CGM offers great potential in monitoring and diagnosis early-stage T1D
- Next-generation CGM innovations focused on data integration and AI prediction
- FreeDM2 trial demonstrated clinically meaningfully A1c reduction with FreeStyle Libre 3 in adults with T2D on basal insulin
- Diabetes and the environment: A bidirectional relationship
- Dr. Viral Shah challenges conventional definitions of “normal” glucose in healthy individuals
- Diabetes Center Berne’s Open Innovation Challenge brings passion and creativity to diabetes technology
- FDA’s Dr. Courtney Lias on new device authorizations, digital health frameworks, and evolving AI frameworks
- Multiple uses of GLP-1 RAs: Current and emerging indications
- C-peptide as a necessary and “more than sufficient” measurement for approving disease-modifying treatments for T1D
- DTS Student Award: Virtual DCCT to estimate GRI as a predictor of complications
- twiist AID shows occlusion alarms detect flow issues within 30 minutes and prompt timely user intervention
- History and progress of ultra-long-acting insulin: Overview on insulin icodec and efsitora alfa
- GLP-1 RAs and muscle atrophy: Emerging treatments and recommendations for addressing muscle loss